ArticleHead & neck2026
Greater Attention to Gingival Cancer and Floor of Mouth Cancer: Based on a Retrospective Analysis of Oral Cancer Across Different Subsites.
Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe gingiva and floor of the mouth are distinct subsites, and oral squamous cell carcinoma (OSCC) originating in these locations warrants further indepth understanding.
methodsThis study enrolled patients with OSCC from 2000 to 2020, and analyzed the clinicopathological characteristics. Kaplan-Meier analysis compared overall survival (OS) and recurrence-free survival (RFS). Univariate analysis and multivariate Cox proportional hazards model examined the risk factors on survival outcomes.
resultsA total of 885 OSCC patients were included, with the most common tumor subsites: oral tongue (41.9%), gingiva (31.8%), and floor of mouth (16.0%). Gingival and floor of mouth showed a higher proportion of advanced stage (65.8%, 66.9%) and significantly poorer OS (3-year: 63.0%, 57.0%; 5-year: 49.8%, 37.3%) and RFS (3-year: 59.1%, 61.3%; 5-year: 55.5%, 57.0%). Neoadjuvant chemotherapy was associated with significantly reduced mortality in gingival cancer (HR = 0.598), while tobacco exposure (HR = 1.952) was associated with a significant increase in mortality in floor of mouth cancer.
conclusionGingival cancer and floor of mouth cancer have a worse prognosis, and thus require greater attention throughout the entire management process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.